BRAF V600E-mutant non-small-cell lung cancer
Prepared with OnCo (onco.cc/prep/braf-v600e-nsclc/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
16 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example BRAF V600E by sequencing, BRAF mutation class, PD-L1 tumour proportion score, Left ventricular function, eye examination and temperature on BRAF plus MEK inhibitors), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (advanced braf v600e, first line), which of the standard options do you recommend and why?
- 6.Am I a candidate for Dabrafenib + trametinib, Dabrafenib, Trametinib or related drugs, and what side effects should I expect?
- 7.How do the results of PHAROS apply to someone like me?
- 8.For my situation (advanced braf v600e, after targeted therapy), which of the standard options do you recommend and why?
- 9.Am I a candidate for Pembrolizumab, Carboplatin, Pemetrexed or related drugs, and what side effects should I expect?
- 10.For my situation (non-v600 braf mutations), which of the standard options do you recommend and why?
- 11.Am I a candidate for Pembrolizumab, Carboplatin, Pemetrexed or related drugs, and what side effects should I expect?
- 12.Are there clinical trials I could join, for example of PHAROS, Encorafenib, Binimetinib?
- 13.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 14.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
- 15.I read that “No randomised trial compares BRAF plus MEK inhibitors with chemoimmunotherapy first line or settles the sequence”. How does that affect my plan?
- 16.I read that “Non-V600 BRAF mutations, half of cases, have no approved targeted therapy”. How does that affect my plan?
The words I may hear
- Tumour proportion score (TPS): The PD-L1 score used in lung cancer: the percentage of tumour cells that stain positive.
- Driver mutation: One of the few mutations in a tumour that actually causes it to grow.
- BRAF V600E mutation: A single spelling change in the BRAF gene that jams a growth switch permanently on.
- Drug resistance (primary and acquired): Why cancer drugs stop working: the tumour either never depended on the target or evolves around the block.
Tests and results to bring
Biomarker results to ask for: BRAF V600E by sequencing (immunohistochemistry as a screen), BRAF mutation class (V600 versus non-V600), PD-L1 tumour proportion score (immunotherapy is active in BRAF-mutant disease), Left ventricular function, eye examination and temperature on BRAF plus MEK inhibitors.
Scans and tests linked to this cancer: Comprehensive genomic profiling.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Advanced BRAF V600E, first line: Dabrafenib plus trametinib or encorafenib plus binimetinib (PHAROS); pembrolizumab with platinum doublet is an alternative, particularly with high PD-L1. (Dabrafenib + trametinib, Dabrafenib, Trametinib, Encorafenib, Binimetinib, PHAROS, Pembrolizumab, BRAF V600E mutation)
- Advanced BRAF V600E, after targeted therapy: Pembrolizumab plus platinum doublet, or the other BRAF plus MEK pair if the first was stopped for toxicity rather than progression. (Pembrolizumab, Carboplatin, Pemetrexed, Encorafenib, Binimetinib)
- Non-V600 BRAF mutations: Treated as driver-negative disease with chemoimmunotherapy; MEK or pan-RAF inhibitor trials. (Pembrolizumab, Carboplatin, Pemetrexed, Trametinib)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.